Home » Stocks » DCPH

Deciphera Pharmaceuticals, Inc. (DCPH)

Stock Price: $31.92 USD -1.36 (-4.09%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 1.84B
Revenue (ttm) 67.18M
Net Income (ttm) -254.98M
Shares Out 57.75M
EPS (ttm) -4.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $31.92
Previous Close $33.28
Change ($) -1.36
Change (%) -4.09%
Day's Open 33.06
Day's Range 31.76 - 33.26
Day's Volume 233,606
52-Week Range 31.76 - 68.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.

Other stocks mentioned: AFMD, ALLK
5 days ago - The Motley Fool

Deciphera (DCPH) doses the first patient in a phase I study evaluating its ULK kinase inhibitor, DCC-3116, for treating advanced/metastatic tumors driven by mutations in RAS/RAF genes.

3 weeks ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...

3 weeks ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...

1 month ago - Business Wire

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in fireside chats at the follo...

1 month ago - Business Wire

The company isn't earning a profit yet, but there are solid reasons why it's worth considering, particularly at its current share price.

2 months ago - The Motley Fool

Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.

2 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 1.85% and 8.89%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the s...

2 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2021, and provided a corporate update. “We are exci...

2 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Trui...

2 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021. In connection with t...

2 months ago - Business Wire

With the trading day about halfway over, the broad markets largely were pushing higher, except for the Dow Jones industrial average.

Other stocks mentioned: BB, LRCX, SHOP, ZM, BHP, SQ, ZYME
3 months ago - 24/7 Wall Street

Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furt...

4 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barc...

4 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB ...

5 months ago - Business Wire

Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.

5 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 5.17% and 4.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...

5 months ago - Zacks Investment Research

Shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 16.03% year over year to ($1....

5 months ago - Benzinga

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2020, and provided a business update. ...

5 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Gugg...

5 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021. ...

5 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, t...

6 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Heal...

6 months ago - Business Wire

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Other stocks mentioned: BMRN, QURE, RGNX
7 months ago - Zacks Investment Research

Deciphera (DCPH) completes enrollment in the phase III study evaluating Qinlock in patients with second-line gastrointestinal stromal tumor.

7 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and ...

7 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, t...

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, h...

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced data presentations from clinical studies of QINLOCK, the Company's switch-control tyrosine kinase inhibito...

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014, a highly...

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual London He...

8 months ago - Business Wire

Deciphera (DCPH) reports a narrower-than-expected loss and sales beat estimates in the third quarter of 2020.

8 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

PETACH TIKVA, Israel and WALTHAM, Mass., Nov. 6, 2020 /PRNewswire/ -- Medison Pharma, a leading international commercial partner for highly innovative therapies, today announced an exclusive distributio...

8 months ago - PRNewsWire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results and provided a business update for the third quarter ended September 30, 2020. “The stron...

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020. In connection w...

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

10 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

10 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

11 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

11 months ago - Business Wire

Deciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 10.45% and 249.26%, respectively, for the quarter ended June 2020.

11 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

11 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

11 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the Australian Therapeutic Goods Administration (TGA) has approved QINLOCK™ (ripretinib), a switch-con...

1 year ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and overall su...

1 year ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sa...

1 year ago - Business Wire

Blueprint Medicines and Deciphera Pharmaceuticals were going toe-to-toe developing treatments for this rare cancer. Investors can now call the winner.

Other stocks mentioned: BPMC
1 year ago - The Motley Fool

After 17 years of clinical work, Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) finally has a marketable product.

1 year ago - Benzinga

About DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment... [Read more...]

Industry
Biotechnology
IPO Date
Sep 28, 2017
CEO
Steven Hoerter
Employees
350
Stock Exchange
NASDAQ
Ticker Symbol
DCPH
Full Company Profile

Financial Performance

In 2020, DCPH's revenue was $42.09 million, an increase of 68.35% compared to the previous year's $25.00 million. Losses were -$266.49 million, 38.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for DCPH stock is "Buy." The 12-month stock price forecast is 71.78, which is an increase of 124.87% from the latest price.

Price Target
$71.78
(124.87% upside)
Analyst Consensus: Buy